Affimed (NASDAQ:AFMD) Receives $32.50 Average PT from Brokerages

Shares of Affimed (NASDAQ:AFMD) have earned an average rating of “Buy” from the four brokerages that are covering the firm, Marketbeat reports. Four investment analysts have rated the stock with a buy recommendation. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $32.50.

A number of research firms recently weighed in on AFMD. Cantor Fitzgerald reissued an “overweight” rating on shares of Affimed in a research report on Monday. Laidlaw increased their price target on Affimed from $15.00 to $25.00 and gave the stock a “buy” rating in a report on Thursday, June 13th. Finally, HC Wainwright restated a “buy” rating and set a $10.00 price objective on shares of Affimed in a report on Friday, September 6th.

Affimed Stock Performance

NASDAQ:AFMD opened at $3.87 on Friday. The stock’s fifty day moving average is $4.56 and its 200 day moving average is $5.20. Affimed has a fifty-two week low of $2.23 and a fifty-two week high of $8.95. The company has a debt-to-equity ratio of 0.13, a quick ratio of 2.71 and a current ratio of 2.71.

Affimed (NASDAQ:AFMD) last announced its earnings results on Wednesday, June 12th. The biopharmaceutical company reported ($1.38) earnings per share for the quarter, beating the consensus estimate of ($1.73) by $0.35. Affimed had a negative net margin of 2,922.74% and a negative return on equity of 155.30%. The business had revenue of $0.17 million for the quarter, compared to the consensus estimate of $1.76 million. As a group, equities research analysts forecast that Affimed will post -3.6 earnings per share for the current fiscal year.

Institutional Trading of Affimed

Several institutional investors and hedge funds have recently modified their holdings of AFMD. Choreo LLC bought a new position in Affimed in the second quarter worth approximately $54,000. Vestal Point Capital LP bought a new position in shares of Affimed during the 4th quarter worth $341,000. Finally, BNP Paribas Financial Markets raised its holdings in shares of Affimed by 39.9% in the fourth quarter. BNP Paribas Financial Markets now owns 571,975 shares of the biopharmaceutical company’s stock valued at $357,000 after acquiring an additional 163,162 shares in the last quarter. Institutional investors own 30.82% of the company’s stock.

Affimed Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and Europe. Its lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase II clinical trial for hodgkin lymphoma, and completed Phase II clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia.